PMID_x stringlengths 4 15 | PMCID_x stringlengths 4 12 | RefID stringlengths 2 4.63k | paragraph stringlengths 1 44.2k ⌀ | AccessionID stringlengths 10 11 | subjects stringlengths 3 3.86k | keywords float64 | PMID_y int64 27M 37.9M | Title stringlengths 16 441 | Authors stringlengths 5 1.2k | Citation stringlengths 36 124 | First Author stringlengths 3 126 | Journal/Book stringlengths 3 42 | Publication Year int64 2.02k 2.03k | Create Date stringlengths 10 10 | PMCID_y stringlengths 10 11 | NIHMS ID stringclasses 335
values | DOI stringlengths 13 44 ⌀ | Key stringlengths 30 31 | ETag stringlengths 32 32 | Article Citation stringlengths 16 71 | Last Updated UTC (YYYY-MM-DD HH:MM:SS) stringlengths 19 19 | License stringclasses 2
values | Retracted stringclasses 2
values |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
['PMC7359576'] | ['32660609'] | ['CR17'] | The primary objective of the study is to evaluate whether the combination of pyrotinib, trastuzumab and AI (Group A) will be superior to trastusumab plus AI (Group B). The primary endpoint is PFS, defined as the time from randomization to the first radiographically documented progression of disease or death from any ca... | PMC7359576 | Study Protocol | null | 32,660,609 | Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial | Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. | BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-2. | Wang C | BMC Cancer | 2,020 | 2020/07/15 | PMC7359576 | null | 10.1186/s12885-020-07143-2 | oa_comm/txt/all/PMC7359576.txt | 509144d7d25c91edabdf727bcf33b544 | BMC Cancer. 2020 Jul 13; 20:653 | 2021-06-19 05:50:23 | CC BY | no |
['PMC7359576'] | ['32660609'] | [] | To be eligible for inclusion in the trial, patients must provide written informed consent before the commencement of any study-related procedures. All patients must be above 18 years old with an Eastern Cooperative Oncology Group performance status 0–2 and a life expectancy of not less than 12 weeks. Eligible patients ... | PMC7359576 | Study Protocol | null | 32,660,609 | Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial | Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. | BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-2. | Wang C | BMC Cancer | 2,020 | 2020/07/15 | PMC7359576 | null | 10.1186/s12885-020-07143-2 | oa_comm/txt/all/PMC7359576.txt | 509144d7d25c91edabdf727bcf33b544 | BMC Cancer. 2020 Jul 13; 20:653 | 2021-06-19 05:50:23 | CC BY | no |
['PMC7359576'] | ['32660609'] | [] | The exclusion criteria are listed as follows: previous systemic non-hormonal anti-cancer therapy in the metastatic or advanced breast cancer setting; previous treatment with pertuzumab or T-DM1 in neoadjuvant or adjuvant treatment; extensive symptomatic visceral disease, severe organ dysfunction or disease considered b... | PMC7359576 | Study Protocol | null | 32,660,609 | Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial | Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. | BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-2. | Wang C | BMC Cancer | 2,020 | 2020/07/15 | PMC7359576 | null | 10.1186/s12885-020-07143-2 | oa_comm/txt/all/PMC7359576.txt | 509144d7d25c91edabdf727bcf33b544 | BMC Cancer. 2020 Jul 13; 20:653 | 2021-06-19 05:50:23 | CC BY | no |
['PMC7359576'] | ['32660609'] | ['MOESM1'] | Eligible patients will be randomized in 2:1 ratio to either Group A or Group B. A stratified randomization will be used to control confounding variables and balance the baseline characteristics between the different treatments. Patients will be stratified by the time since prior ET (< 12 months/≥ 12 months/no prior ET)... | PMC7359576 | Study Protocol | null | 32,660,609 | Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial | Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. | BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-2. | Wang C | BMC Cancer | 2,020 | 2020/07/15 | PMC7359576 | null | 10.1186/s12885-020-07143-2 | oa_comm/txt/all/PMC7359576.txt | 509144d7d25c91edabdf727bcf33b544 | BMC Cancer. 2020 Jul 13; 20:653 | 2021-06-19 05:50:23 | CC BY | no |
['PMC7359576'] | ['32660609'] | [] | The primary objective of this study is to compare the PFS between the two groups. The hypothesis is based on hazard ratio (HR): H0: HR = 1; Ha: HR ≠ 1. In the case of 2:1 allocation, a sample of 180 evaluable patients with 144 events is expected to provide 80% power (significance level 0.05) to detect an improvement in... | PMC7359576 | Study Protocol | null | 32,660,609 | Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial | Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. | BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-2. | Wang C | BMC Cancer | 2,020 | 2020/07/15 | PMC7359576 | null | 10.1186/s12885-020-07143-2 | oa_comm/txt/all/PMC7359576.txt | 509144d7d25c91edabdf727bcf33b544 | BMC Cancer. 2020 Jul 13; 20:653 | 2021-06-19 05:50:23 | CC BY | no |
['PMC7359576'] | ['32660609'] | [] | The difference in PFS (primary endpoint) will be estimated using the full analysis set (FAS) in a stratified log-rank test accounting for all stratification factors and a Cox proportional hazards model to explore baseline factors that may affect PFS. Secondary objectives include comparisons of OS, ORR, TTR, DoR, CBR, Q... | PMC7359576 | Study Protocol | null | 32,660,609 | Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial | Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. | BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-2. | Wang C | BMC Cancer | 2,020 | 2020/07/15 | PMC7359576 | null | 10.1186/s12885-020-07143-2 | oa_comm/txt/all/PMC7359576.txt | 509144d7d25c91edabdf727bcf33b544 | BMC Cancer. 2020 Jul 13; 20:653 | 2021-06-19 05:50:23 | CC BY | no |
['PMC7359576'] | ['32660609'] | [] | The type, grade and frequency of AEs will be recorded. AEs and abnormal findings in laboratory tests will be listed with the relationship to the study treatments. The AE summary tables for crossover patients will include all AEs that occurred after the start of crossover treatment until the end of the 30-day follow-up ... | PMC7359576 | Study Protocol | null | 32,660,609 | Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial | Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. | BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-2. | Wang C | BMC Cancer | 2,020 | 2020/07/15 | PMC7359576 | null | 10.1186/s12885-020-07143-2 | oa_comm/txt/all/PMC7359576.txt | 509144d7d25c91edabdf727bcf33b544 | BMC Cancer. 2020 Jul 13; 20:653 | 2021-06-19 05:50:23 | CC BY | no |
['PMC7359576'] | ['32660609'] | ['CR11', 'CR12'] | This study aims to verify that the addition of pyrotinib to trastuzumab plus AI may convey survival benefits to HR+/HER2+ MBC or LABC patients. Since there is a scarcity of existing trials on AI with dual HER2 blockade, this study aims to generate evidence that pyrotinib combined with trastusumab and AI could be used a... | PMC7359576 | Study Protocol | null | 32,660,609 | Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial | Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. | BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-2. | Wang C | BMC Cancer | 2,020 | 2020/07/15 | PMC7359576 | null | 10.1186/s12885-020-07143-2 | oa_comm/txt/all/PMC7359576.txt | 509144d7d25c91edabdf727bcf33b544 | BMC Cancer. 2020 Jul 13; 20:653 | 2021-06-19 05:50:23 | CC BY | no |
['PMC7368084'] | ['32681124'] | [] | The reliable quantification of individuals’ physiological response to acute exercise bouts are of major importance for monitoring training. Both, subjective as well as objective markers are used to control athletes’ training in accordance with individual abilities. When training stimuli are wrongly applied due to a lac... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | ['Fig1', 'Fig1', 'Fig1', 'Fig1', 'Fig2', 'Fig2', 'Fig2', 'Fig2', 'Fig2', 'Fig2', 'Fig3', 'Fig3'] | Results indicated that TBARS (F3= 79.43;p< 0.001), LDH (F3= 208.72;p< 0.001), CK (F1.44= 153.09;p< 0.001) and cortisol (F2.33= 99.89;p< 0.001) showed significant main effects over the measuring time points (MTPs). Both exercise trials induced an increase of TBARS (Fig.1a), LDH (Fig.1b) and CK (Fig.1d) immediately after... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | ['Fig4', 'Fig4', 'Fig4'] | No changes over time were found for the 5-bound distance (Fig.4a). However, for this test an excellent ICC of 0.96 was calculated. The two-way ANOVA revealed significant differences in both MVCs (knee flexion:F2.61= 14.18,p< 0.001; knee extension:F2.49= 25.01,p< 0.001) parameters over the MTPs. MVCs of the knee extenso... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | ['Fig5', 'Fig5'] | The two-way ANOVA revealed significant changes over time for RPE values (Fig.5a) (F3= 345.19;p< 0.001). For the test–retest reliability, a poor ICC of 0.49 was found. Data from the acute multidimensional mood state showed lower scores immediately after the RFTs as well as three hours after exercise. We compared this to... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | [] | A correlation was found between MVC in knee extension and TBARS immediately after (r= 0.26,p= 0.044), 3 h after (r= 0.34,p= 0.009) and 24 h after (r= 0.30,p= 0.020) the RFT at testing day 1 (TD1). Interestingly, there were also correlations in the changes between the pre-exercise value and 3 h after (r= -0.30,p= 0.021)... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | [] | No differences between trained and untrained participants were found for the changes of any parameter over time. With regard to the reliability, CK revealed a poor reliability in the subgroup of trained individuals (ICC = 0.49), while reliability was categorized as good (ICC = 0.84) for the untrained group. The opposit... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | [] | The novel findings of the present study are the high reliability of TBARS, LDH, IL-1RA, MCV, HGB, PLT, RBC, HCT, and MCHC after two identical controlled bouts of endurance exercise, suggesting their suitability as blood-based biomarkers for monitoring physiological exercise response and recovery status in endurance ath... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | ['Tab1'] | For a test–retest study design, 106 trained and untrained male and female subjects, aged 19–43 years, were recruited randomly and voluntarily to participate. 62 (31 male and 31 female) of them completed all examinations and were included in statistical analysis. According to the American College of Sports Medicine guid... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | [] | The first step of the experimental approach contains testing of endurance capacity parameters to monitor the kinetics of various markers during further two identical strenuous exercise trials under controlled conditions. Subjects were tested for their endurance capacity during a continuous progressive exercise field te... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | [] | Approximately one week after the preliminary test, first testing day TD1 of strenuous exercise trial took place. Both testing days (TDs) started between 8:00 and 9:00 am for each subject. Prior to the TDs, subjects were instructed on several standardized conditions to which they had to comply. From four days before the... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC7368084'] | ['32681124'] | [] | Data of all subjects are presented as means ± standard deviation of the mean and the minimum and maximum values. In cases of normal or log-normal distribution (Kolmogorov–Smirnov test), data were analyzed using the two-way ANOVA to observe mean differences between the MTPs depending on the TDs. If analysis revealed any... | PMC7368084 | Article | null | 32,681,124 | Reliability and suitability of physiological exercise response and recovery markers | Reichel T, Boßlau TK, Palmowski J, Eder K, Ringseis R, Mooren FC, Walscheid R, Bothur E, Samel S, Frech T, Philippe M, Krüger K. | Sci Rep. 2020 Jul 17;10(1):11924. doi: 10.1038/s41598-020-69280-9. | Reichel T | Sci Rep | 2,020 | 2020/07/19 | PMC7368084 | null | 10.1038/s41598-020-69280-9 | oa_comm/txt/all/PMC7368084.txt | 60dc8c9047a47c5b674faee05945d073 | Sci Rep. 2020 Jul 17; 10:11924 | 2021-06-19 05:51:30 | CC BY | no |
['PMC6001778'] | ['29578260'] | ['nbm3905-bib-0001', 'nbm3905-bib-0002', 'nbm3905-bib-0003', 'nbm3905-bib-0004', 'nbm3905-bib-0005', 'nbm3905-bib-0006', 'nbm3905-bib-0007', 'nbm3905-bib-0008', 'nbm3905-bib-0009', 'nbm3905-bib-0010', 'nbm3905-bib-0011', 'nbm3905-bib-0012', 'nbm3905-bib-0013', 'nbm3905-bib-0014', 'nbm3905-bib-0015', 'nbm3905-bib-0016',... | Exercising muscle tissue has been studied for several decades using magnetic resonance spectroscopy (MRS).(1,2) In particular, time‐resolved31P MRS is a valuable non‐invasive tool to investigate the metabolic response of exercising muscle in humans. Physiologically relevant parameters such as pH, PCr recovery time cons... | PMC6001778 | Research Article; Research Articles | null | 29,578,260 | Dynamic multivoxel-localized (31) P MRS during plantar flexion exercise with variable knee angle | Niess F, Fiedler GB, Schmid AI, Laistler E, Frass-Kriegl R, Wolzt M, Moser E, Meyerspeer M. | NMR Biomed. 2018 Jun;31(6):e3905. doi: 10.1002/nbm.3905. Epub 2018 Mar 26. | Niess F | NMR Biomed | 2,018 | 2018/03/27 | PMC6001778 | null | 10.1002/nbm.3905 | oa_comm/txt/all/PMC6001778.txt | 4a52d80b931f0743e72c7485bfb79cf6 | NMR Biomed. 2018 Jun 26; 31(6):e3905 | 2021-06-18 17:20:58 | CC BY | no |
['PMC6001778'] | ['29578260'] | ['nbm3905-bib-0024', 'nbm3905-bib-0025', 'nbm3905-bib-0023', 'nbm3905-bib-0023', 'nbm3905-bib-0023', 'nbm3905-bib-0023', 'nbm3905-bib-0026', 'nbm3905-bib-0027', 'nbm3905-bib-0028', 'nbm3905-bib-0003', 'nbm3905-bib-0004', 'nbm3905-bib-0005'] | Magnetic resonance spectroscopy data from gastrocnemius medialis and soleus of healthy volunteers were acquired simultaneously during rest, exercise and recovery, repeatedly for each knee angle. 12 subjects (8 males and 4 females, age 26.4 ± 4.9 years, body mass index 22.1 ± 1.7 kg/m2) participated in the study after h... | PMC6001778 | Research Article; Research Articles | null | 29,578,260 | Dynamic multivoxel-localized (31) P MRS during plantar flexion exercise with variable knee angle | Niess F, Fiedler GB, Schmid AI, Laistler E, Frass-Kriegl R, Wolzt M, Moser E, Meyerspeer M. | NMR Biomed. 2018 Jun;31(6):e3905. doi: 10.1002/nbm.3905. Epub 2018 Mar 26. | Niess F | NMR Biomed | 2,018 | 2018/03/27 | PMC6001778 | null | 10.1002/nbm.3905 | oa_comm/txt/all/PMC6001778.txt | 4a52d80b931f0743e72c7485bfb79cf6 | NMR Biomed. 2018 Jun 26; 31(6):e3905 | 2021-06-18 17:20:58 | CC BY | no |
['PMC6001778'] | ['29578260'] | ['nbm3905-bib-0023', 'nbm3905-tbl-0001', 'nbm3905-fig-0001', 'nbm3905-fig-0001', 'nbm3905-fig-0001', 'nbm3905-fig-0002', 'nbm3905-fig-0002', 'nbm3905-fig-0002', 'nbm3905-tbl-0001', 'nbm3905-tbl-0002', 'nbm3905-tbl-0001', 'nbm3905-fig-0003', 'nbm3905-tbl-0001', 'nbm3905-fig-0003', 'nbm3905-tbl-0001', 'nbm3905-fig-0003',... | The SNR of PCr at rest did not change significantly between knee angles and was 120 ± 24 in gastrocnemius medialis and 42 ± 12 in soleus on average across all subjects (mean ± SD). The linewidths, quantified throughout the experiment, were 7.8 ± 1.2 Hz in gastrocnemius medialis and 8.3 ± 1.5 Hz in soleus, which is cons... | PMC6001778 | Research Article; Research Articles | null | 29,578,260 | Dynamic multivoxel-localized (31) P MRS during plantar flexion exercise with variable knee angle | Niess F, Fiedler GB, Schmid AI, Laistler E, Frass-Kriegl R, Wolzt M, Moser E, Meyerspeer M. | NMR Biomed. 2018 Jun;31(6):e3905. doi: 10.1002/nbm.3905. Epub 2018 Mar 26. | Niess F | NMR Biomed | 2,018 | 2018/03/27 | PMC6001778 | null | 10.1002/nbm.3905 | oa_comm/txt/all/PMC6001778.txt | 4a52d80b931f0743e72c7485bfb79cf6 | NMR Biomed. 2018 Jun 26; 31(6):e3905 | 2021-06-18 17:20:58 | CC BY | no |
['PMC6001778'] | ['29578260'] | ['nbm3905-bib-0016', 'nbm3905-bib-0020', 'nbm3905-bib-0004', 'nbm3905-bib-0022', 'nbm3905-bib-0029', 'nbm3905-bib-0030', 'nbm3905-bib-0004', 'nbm3905-bib-0011', 'nbm3905-bib-0003', 'nbm3905-bib-0004', 'nbm3905-bib-0014', 'nbm3905-fig-0004', 'nbm3905-fig-0004', 'nbm3905-bib-0004', 'nbm3905-fig-0004', 'nbm3905-bib-0016',... | A relation between knee angle and the recruitment pattern of gastrocnemius and soleus is expected according to anatomy and has been explored with1H MRI16and31P MRS.20The purpose of this study was to investigate the effect of knee angle on metabolic changes in those muscles in further detail, in order to establish a mor... | PMC6001778 | Research Article; Research Articles | null | 29,578,260 | Dynamic multivoxel-localized (31) P MRS during plantar flexion exercise with variable knee angle | Niess F, Fiedler GB, Schmid AI, Laistler E, Frass-Kriegl R, Wolzt M, Moser E, Meyerspeer M. | NMR Biomed. 2018 Jun;31(6):e3905. doi: 10.1002/nbm.3905. Epub 2018 Mar 26. | Niess F | NMR Biomed | 2,018 | 2018/03/27 | PMC6001778 | null | 10.1002/nbm.3905 | oa_comm/txt/all/PMC6001778.txt | 4a52d80b931f0743e72c7485bfb79cf6 | NMR Biomed. 2018 Jun 26; 31(6):e3905 | 2021-06-18 17:20:58 | CC BY | no |
['PMC6001778'] | ['29578260'] | [] | The knee angle influences the distribution of workload between gastrocnemius and soleus muscles during plantar flexion. Consequently, it affects metabolic parameters measured with31P MRS during exercise and recovery. The recruitment of gastrocnemius decreased significantly when increasing the knee angle, which was refl... | PMC6001778 | Research Article; Research Articles | null | 29,578,260 | Dynamic multivoxel-localized (31) P MRS during plantar flexion exercise with variable knee angle | Niess F, Fiedler GB, Schmid AI, Laistler E, Frass-Kriegl R, Wolzt M, Moser E, Meyerspeer M. | NMR Biomed. 2018 Jun;31(6):e3905. doi: 10.1002/nbm.3905. Epub 2018 Mar 26. | Niess F | NMR Biomed | 2,018 | 2018/03/27 | PMC6001778 | null | 10.1002/nbm.3905 | oa_comm/txt/all/PMC6001778.txt | 4a52d80b931f0743e72c7485bfb79cf6 | NMR Biomed. 2018 Jun 26; 31(6):e3905 | 2021-06-18 17:20:58 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-bib-0001', 'jde15950-bib-0001', 'jde15950-bib-0002', 'jde15950-bib-0003', 'jde15950-bib-0004', 'jde15950-bib-0005', 'jde15950-bib-0006', 'jde15950-bib-0007', 'jde15950-bib-0008', 'jde15950-bib-0009', 'jde15950-bib-0010', 'jde15950-bib-0011', 'jde15950-bib-0012', 'jde15950-bib-0013'] | Dry skin is observed in 50%–90% of patients with end‐stage renal disease and persists or even worsens despite dialysis.1Pruritus is also reported in 12%–90% of patients with end‐stage renal disease.1Suggested causes of pruritus in patients with end‐stage renal disease undergoing dialysis include dry skin, the influence... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | [] | This study was approved by the ethics review committees of Nippon Medical School (16 June 2017; Approval No. 229006) and Adachi Kyosai Hospital (24 August 2017), and was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (No. UMIN000029360). The study was conducted in co... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | [] | This study was conducted at the Kidney Disease Clinic of Nippon Medical School, Koyama Memorial Hospital, and Moka Hospital from October 2018 to May 2019. | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-fig-0001', 'jde15950-fig-0001', 'jde15950-bib-0014', 'jde15950-bib-0015'] | This was a multicenter, open‐label, randomized, before–after, parallel‐group comparative study. The study schedule is shown in Figure1. Participants were randomized in a 1:1 ratio to groups A and B. In group A, the study product was applied for 2 weeks (period I), while in group B, the study product was applied for 8 w... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-bib-0013'] | The study participants were clinically stable patients with chronic kidney disease undergoing hemodialysis. Their age ranged from 20 to 80 years on the day on which they gave informed consent, and all had been diagnosed with xerosis in the hypochondriac region and had dialysis‐associated pruritus at the start of the st... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-fig-0002', 'jde15950-tbl-0001'] | Sex, age, height, and body weight were recorded on the day on which participants gave informed consent. Although the target sample size was 76, enrollment was stopped after 71 patients were enrolled because almost no participants dropped out and the required number for analysis was reached early. Of the 71 enrolled pat... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-tbl-0002'] | Adherence to study treatment was assessed at weeks 1, 2, 3, 4, 6, and 8 based on the patient's self‐completed diary and an interview with the participant. The following five categories were used to assess adherence: “completely or nearly as directed (applied on ≥90% of occasions),” “fairly as directed (applied on 75% t... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-bib-0013'] | The WCSC was measured on each day of evaluation 1 to 2 hours after the start of a dialysis session. One site in either the left or right hypochondriac region was designated as the measurement site for each participant. The measurement was conducted using the same instrument as in the previous study13(Corneometer and Mu... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | [] | A board‐certified dermatologist centrally rated the severity of skin dryness on a five‐point scale according to the criteria shown in Supporting Information Table S1, based on photographs of the hypochondriac region (at the measurement site for WCSC) taken on each day of evaluation. | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | [] | Participants rated skin pruritus at the study product application site on a 100‐mm visual analog scale (VAS; 0 mm indicating no pruritus and 100 mm indicating the worst possible pruritus) before the start of dialysis on each day of evaluation. | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-bib-0005'] | The participants assessed skin disease‐specific QOL at weeks 0, 2, 4, and 8 by completing the DLQI questionnaire,5which comprises six domains: “Symptoms and feelings” (questions 1 and 2), “Daily activities” (questions 3 and 4), “Leisure activities” (questions 5 and 6), “Work and school” (question 7), “Personal relation... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | [] | Adverse events that occurred during weeks 0–8 were investigated. | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | [] | The efficacy analysis set comprised participants who used the study product during weeks 0 to 8 and for whom any efficacy data were available. The safety analysis set comprised participants for whom any safety data were available after using the study product. The analysis of patient demographics included all patients ... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-fig-0003'] | The WCSC over time is shown in Figure3and Table S2. The mean WCSC at week 4 (primary endpoint) was 28.8 ± 10.4 AU in group A and 36.4 ± 12.2 AU in group B (P= 0.0068, estimated difference −7.6, 95% confidence interval −13.0 to −2.17). Compared with the value at week 0 (26.0 ± 9.0 AU in group A, 25.2 ± 10.0 AU in group ... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-fig-0004'] | The skin dryness score over time is shown in Figure4and Table S3. At week 2, the score significantly decreased in both groups (group A: 1.4 ± 0.7 at week 0 and 0.3 ± 0.5 at WEEK 2,P< 0.00001; group B: 1.3 ± 0.7 at week 0 and 0.3 ± 0.5 at week 2,P< 0.00001). After week 2, the score showed a tendency to increase only in ... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-fig-0005'] | The pruritus VAS score over time is shown in Figure5and Table S4. In both groups, the pruritus VAS score significantly decreased from week 0 (40.0 ± 26.3 mm in group A, 44.8 ± 23.7 mm in group B) to the end of period I (week 2) (16.5 ± 16.1 mm in group A, 20.1 ± 18.7 mm in group B;P< 0.00001 for both vs week 0). After ... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-fig-0006'] | The DLQI score over time is shown in Figure6and Table S5. At week 8, the total DLQI score was significantly lower at 0.7 ± 1.2 in group B compared with 1.4 ± 1.3 in group A (P= 0.0278, estimated difference 0.67, 95% confidence interval 0.07‐1.26). By domain, the “Symptoms and feelings” subscore over time was similar to... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-tbl-0003'] | In total, 126 adverse events were reported in 51 of the 71 participants in the safety analysis set (Table3). One participant in group B had two adverse events (rash and erythema) that might have been related to the study product, and this patient was withdrawn from the study. These adverse events resolved after discont... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | ['jde15950-bib-0013', 'jde15950-bib-0013', 'jde15950-bib-0014', 'jde15950-bib-0016', 'jde15950-bib-0017'] | Heparinoid‐containing products are widely used for xerosis caused by various factors, including dialysis, in Japan. However, no reports other than our previous study13have described the effectiveness of such products for xerosis in patients undergoing dialysis as evaluated with an objective indicator such as the WCSC. ... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | [] | The Kidney Disease Clinic of Nippon Medical School, Department of Nephrology of Nippon Medical School, Department of Dermatology of Nippon Medical School, Koyama Memorial Hospital, and Moka Hospital were paid by Maruho Co., Ltd for conducting this study. Yukie Yoshida, who presented the study results at the American So... | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC8453556'] | ['34041789'] | [] | Parts of the results of this study were presented at the ASN Kidney Week 2019 (November 2019, Washington, DC) and the 40th Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (December 2019, Tokyo). | PMC8453556 | Original Article; Original Articles | null | 34,041,789 | Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open-label, randomized verification study | Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, Kishida M, Nakamura H, Kanakubo A, Tsuruoka S. | J Dermatol. 2021 Sep;48(9):1327-1335. doi: 10.1111/1346-8138.15950. Epub 2021 May 26. | Yoshida Y | J Dermatol | 2,021 | 2021/05/27 | PMC8453556 | null | 10.1111/1346-8138.15950 | oa_comm/txt/all/PMC8453556.txt | 490533980c761d853cd07b3aaaf1d5e4 | J Dermatol. 2021 Sep 26; 48(9):1327-1335 | 2021-11-06 06:49:53 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.ref001', 'pmed.1003411.ref002', 'pmed.1003411.ref003', 'pmed.1003411.ref003', 'pmed.1003411.ref004', 'pmed.1003411.ref005', 'pmed.1003411.ref006', 'pmed.1003411.ref007', 'pmed.1003411.ref008'] | Neonatal hypoglycemia is common, affecting up to 15% of newborn babies [1] and 50% of those with risk factors (preterm, infant of a mother with diabetes, or high or low birthweight) [2,3]. First-line treatment with oral 40% dextrose gel in addition to feeding is safe and effective [3], but if hypoglycemia persists, int... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.ref009'] | This multicenter, double-blinded, 2-arm, parallel, placebo-controlled randomized trial was conducted at 18 Australian and New Zealand maternity hospitals (trial registration ACTRN12614001263684). The study protocol has been published previously [9]. Babies were eligible if they were born at risk of hypoglycemia (define... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | [] | This study was approved by the New Zealand Health and Disability Ethics Committee (13NTA8), the Human Research Ethics Committee at the Women’s and Children’s Hospital, Adelaide (HREC/16/WCHN/86), and the institutional review committees at each participating hospital. Parents gave written informed consent, which was sou... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | [] | The randomization schedule was prepared by the study statistician, who was not involved with any clinical aspect of the trial, and was stratified by study site and reason for risk of hypoglycemia (infant mother with diabetes, preterm, small, or large) with varied block size using the Plan procedure of SAS (version 9.4;... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.ref008'] | Randomized babies received a single dose of 0.5 ml/kg study gel at 1 hour after birth. This dose (200 mg/kg of 40% dextrose) was selected based on the pre-hPOD dosage trial [8] as having greatest efficacy with fewest limitations. The buccal mucosa was dried with a gauze swab before the study gel was massaged into the m... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | [] | The primary outcome was admission to NICU (or Special Care Baby Unit for hospitals that used that name) for >4 hours. Secondary outcomes were hypoglycemia (any blood glucose concentration < 2.6 mmol/l in the first 48 hours), admission to NICU for hypoglycemia, hyperglycemia (any blood glucose concentration > 10 mmol/l)... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.ref008', 'pmed.1003411.ref003'] | Based on our previous data from Auckland City [8] and Waikato Hospitals [3], we estimated that 10% of at-risk babies would require admission to NICU. A trial of 2,129 babies (1,014 in each arm, with continuity correction and allowing for a 5% dropout rate) would have 90% power to detect a 40% relative reduction (absolu... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | [] | The trial was overseen by an independent data monitoring committee and safety monitoring committee. No interim analyses were planned or undertaken. All analyses were prespecified and carried out using a modified intention-to-treat approach, in which babies randomized in error (i.e., who did not meet eligibility criteri... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.g001', 'pmed.1003411.t001'] | Eighteen participating hospitals recruited 2,149 babies between 9 January 2015 and 5 May 2019 (range 5–535 babies per site). Sixteen babies were randomized in error and were excluded from the analysis, leaving 2,133 in the intention-to-treat analysis, 1,070 randomized to dextrose gel and 1,063 to placebo (Fig 1). This ... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | [] | Most babies (2,093/2,133; 98%) received the allocated study gel. Study gel was well tolerated by 2,044/2,097 (97%) babies (defined as none or only a few drops of gel spilled). Most blood glucose measurements were done using a glucose oxidase method (9,583/11,481; 83.5%), and the mean (SD) number of glucose measurements... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.t002'] | Three families withdrew consent to collect the primary outcome of NICU admission (all in the placebo group) and were therefore assumed to have been admitted to NICU for the intention-to-treat analysis. The overall rate of NICU admission was 9.9%, and was similar in babies randomized to dextrose and placebo gel (Table 2... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.t002', 'pmed.1003411.t002'] | Babies randomized to dextrose gel had higher initial blood glucose concentrations (mean difference 0.19 mmol/l; 95% CI 0.13, 0.25 mmol/l;p< 0.001) and were less likely to become hypoglycemic (adjusted relative risk [aRR] 0.88; 95% CI 0.80, 0.98;p= 0.02) (Table 2). However, the rate of treatment for hypoglycemia did not... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.t002'] | Two babies in each group died before discharge home; no deaths were considered likely to be related to the study intervention. One baby randomized to placebo gel had seizures 3 days after discharge, which were thought to be benign. Sepsis was suspected in 17 babies in each group (aRR 0.99; 95% CI 0.52, 1.93;p= 0.99), b... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.g002', 'pmed.1003411.g002', 'pmed.1003411.t003'] | The rate of NICU admission varied widely across study sites (range 6.7% to 32.1%), and was higher in Australian than in New Zealand centers (113/774, 14.6%, versus 98/1,359, 7.2%; aRR 2.12; 95% CI 1.64, 2.75;p <0.001). However, there was no evidence that dextrose gel altered the rate of NICU admission compared to place... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | [] | (A) NICU admission; (B) hypoglycemia. Horizontal lines indicate adjusted relative risks (aRRs) and 95% confidence intervals. | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.t003', 'pmed.1003411.t003'] | Sensitivity analyses excluding babies with protocol deviations, babies who did not receive any of the assigned study gel (modified per protocol analysis), or babies for whom the primary outcome was not known did not change any of the findings (Table 3). Findings were also similar if only glucose measurements using a gl... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.g003', 'pmed.1003411.g004'] | Adjustment for other potential confounders (see “Statistical analysis”) did not change any of the key findings, with relative risks for NICU admission of 1.08–1.12 (p= 0.57–0.37) across the 5 prespecified adjustments. There was no evidence that the effect of dextrose gel was related to the rate of NICU admission, or to... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | [] | (A) NICU admission; (B) hypoglycemia. Two study sites are excluded due to small numbers of babies recruited. | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | [] | Time is rounded into hour bins. Glucose concentrations are different between groups at 2 hours (p< 0.01). | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC7842885'] | ['33507929'] | ['pmed.1003411.ref008', 'pmed.1003411.ref002', 'pmed.1003411.ref003', 'pmed.1003411.ref010', 'pmed.1003411.ref003', 'pmed.1003411.ref008', 'pmed.1003411.ref008', 'pmed.1003411.ref011', 'pmed.1003411.ref008', 'pmed.1003411.ref003', 'pmed.1003411.ref012', 'pmed.1003411.ref013', 'pmed.1003411.ref014'] | We have previously shown that a single dose of 200 mg/kg prophylactic dextrose gel reduced the incidence of hypoglycemia in babies at risk [8]. We therefore hypothesized that in at-risk but otherwise well babies, prophylactic dextrose gel may reduce NICU admission, with potential health, societal, and cost benefits. Ho... | PMC7842885 | Research Article; Medicine and Health Sciences; Medical Conditions; Metabolic Disorders; Hypoglycemia; Physical Sciences; Chemistry; Chemical Compounds; Organic Compounds; Carbohydrates; Monosaccharides; Glucose; Physical Sciences; Chemistry; Organic Chemistry; Organic Compounds; Carbohydrates; Monosaccharides; Glucose... | null | 33,507,929 | Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial | Harding JE, Hegarty JE, Crowther CA, Edlin RP, Gamble GD, Alsweiler JM; hPOD Study Group. | PLoS Med. 2021 Jan 28;18(1):e1003411. doi: 10.1371/journal.pmed.1003411. eCollection 2021 Jan. | Harding JE | PLoS Med | 2,021 | 2021/01/28 | PMC7842885 | null | 10.1371/journal.pmed.1003411 | oa_comm/txt/all/PMC7842885.txt | fa226a160f12232cf4b09881fd6c8c28 | PLoS Med. 2021 Jan 28; 18(1):e1003411 | 2021-06-19 07:05:26 | CC BY | no |
['PMC6020185'] | ['29940933'] | ['CR1', 'CR2', 'CR3', 'CR4', 'CR5', 'CR6', 'CR9', 'CR6', 'CR10', 'CR10', 'CR11', 'CR12', 'CR13', 'CR14', 'CR17', 'CR18', 'CR19'] | Overactive bladder (OAB) is defined by the International Continence Society (ICS) as urinary urgency in the absence of any known infection or other obvious pathology. OAB is usually characterized by frequency and nocturia, but may or may not cause urinary incontinence [1]. It has been shown to affect up to 36% of adult... | PMC6020185 | Research Article | null | 29,940,933 | The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study | Zachariou A, Mamoulakis C, Filiponi M, Dimitriadis F, Giannakis J, Skouros S, Tsounapi P, Takenaka A, Sofikitis N. | BMC Urol. 2018 Jun 25;18(1):61. doi: 10.1186/s12894-018-0377-9. | Zachariou A | BMC Urol | 2,018 | 2018/06/27 | PMC6020185 | null | 10.1186/s12894-018-0377-9 | oa_comm/txt/all/PMC6020185.txt | 3a37c058971db58166c4c499a921543d | BMC Urol. 2018 Jun 25; 18:61 | 2021-06-18 17:23:57 | CC BY | no |
['PMC6020185'] | ['29940933'] | ['CR1', 'CR20', 'CR21', 'CR22', 'CR23'] | Between January 2016 and December 2016, 85 sexually active women with confirmed OAB, had referred to the Urogynecology outpatient clinic and were prospectively enrolled in this study. OAB was determined using the International Continence Society definition [1]. The urination frequency of all women was 8 or more times a... | PMC6020185 | Research Article | null | 29,940,933 | The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study | Zachariou A, Mamoulakis C, Filiponi M, Dimitriadis F, Giannakis J, Skouros S, Tsounapi P, Takenaka A, Sofikitis N. | BMC Urol. 2018 Jun 25;18(1):61. doi: 10.1186/s12894-018-0377-9. | Zachariou A | BMC Urol | 2,018 | 2018/06/27 | PMC6020185 | null | 10.1186/s12894-018-0377-9 | oa_comm/txt/all/PMC6020185.txt | 3a37c058971db58166c4c499a921543d | BMC Urol. 2018 Jun 25; 18:61 | 2021-06-18 17:23:57 | CC BY | no |
['PMC6020185'] | ['29940933'] | ['Tab1', 'Tab2', 'Tab3', 'Tab4', 'Tab5', 'Tab6'] | All tested variables showed significant departures from the normal distribution. The only exceptions were the pre- and post-observation/treatment total scores of sexual function and the voided volumes. Consequently, non-parametric tests (Mann Whitney U test and Wilcoxon signed-rank test, respectively) were performed fo... | PMC6020185 | Research Article | null | 29,940,933 | The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study | Zachariou A, Mamoulakis C, Filiponi M, Dimitriadis F, Giannakis J, Skouros S, Tsounapi P, Takenaka A, Sofikitis N. | BMC Urol. 2018 Jun 25;18(1):61. doi: 10.1186/s12894-018-0377-9. | Zachariou A | BMC Urol | 2,018 | 2018/06/27 | PMC6020185 | null | 10.1186/s12894-018-0377-9 | oa_comm/txt/all/PMC6020185.txt | 3a37c058971db58166c4c499a921543d | BMC Urol. 2018 Jun 25; 18:61 | 2021-06-18 17:23:57 | CC BY | no |
['PMC6020185'] | ['29940933'] | ['CR24', 'CR7', 'CR25', 'CR26', 'CR27', 'CR28', 'CR29', 'CR30', 'CR6', 'CR30', 'CR7', 'CR25', 'CR28', 'CR31', 'CR32', 'CR33', 'CR34', 'CR35', 'CR36', 'CR37', 'CR35', 'CR35', 'CR38', 'CR39', 'CR40', 'CR40', 'Fig1'] | This study is one of the few, to our knowledge, to demonstrate the effect of mirabegron, the first β-3 adrenoceptor agonist, on sexual function of women suffering from OAB. Our data has indicated that after 3 months evaluation, females with OAB receiving mirabegron 50 mg revealed statistically significant changes in FS... | PMC6020185 | Research Article | null | 29,940,933 | The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study | Zachariou A, Mamoulakis C, Filiponi M, Dimitriadis F, Giannakis J, Skouros S, Tsounapi P, Takenaka A, Sofikitis N. | BMC Urol. 2018 Jun 25;18(1):61. doi: 10.1186/s12894-018-0377-9. | Zachariou A | BMC Urol | 2,018 | 2018/06/27 | PMC6020185 | null | 10.1186/s12894-018-0377-9 | oa_comm/txt/all/PMC6020185.txt | 3a37c058971db58166c4c499a921543d | BMC Urol. 2018 Jun 25; 18:61 | 2021-06-18 17:23:57 | CC BY | no |
['PMC6020185'] | ['29940933'] | [] | Females with OAB should be assessed for their sexual function to provide better quality of life. According to the aforementioned data, OAB treatment with mirabegron improves female sexual function. The above documented improvement in female sexual function might be due to the improvement in the consequences of OAB path... | PMC6020185 | Research Article | null | 29,940,933 | The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study | Zachariou A, Mamoulakis C, Filiponi M, Dimitriadis F, Giannakis J, Skouros S, Tsounapi P, Takenaka A, Sofikitis N. | BMC Urol. 2018 Jun 25;18(1):61. doi: 10.1186/s12894-018-0377-9. | Zachariou A | BMC Urol | 2,018 | 2018/06/27 | PMC6020185 | null | 10.1186/s12894-018-0377-9 | oa_comm/txt/all/PMC6020185.txt | 3a37c058971db58166c4c499a921543d | BMC Urol. 2018 Jun 25; 18:61 | 2021-06-18 17:23:57 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['B1-nutrients-11-00640', 'B2-nutrients-11-00640', 'B3-nutrients-11-00640', 'B1-nutrients-11-00640', 'B4-nutrients-11-00640', 'B5-nutrients-11-00640', 'B6-nutrients-11-00640', 'B7-nutrients-11-00640', 'B8-nutrients-11-00640', 'B9-nutrients-11-00640', 'B10-nutrients-11-00640', 'B11-nutrients-11-00640', 'B12-nutrients-11... | Cardiovascular disease (CVD) is the leading cause of death worldwide. The annual mortality from CVD is higher than from any other cause [1,2]. In the last 40 years, a rapid increase in the prevalence of cardiovascular diseases has been observed. In 2030, it is estimated that approximately 23.3 million people will die f... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | [] | The present study was registered athttp://clinicaltrials.govunder the number NCT02042742. | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['B48-nutrients-11-00640'] | One hundred and five subjects aged 45–65 years were recruited for the present study by the Nutrition Department of La Paz University Hospital (HULP), Madrid (Spain). The inclusion criteria to be eligible for the study were as follows: aged between 45 and 65 years, having a suitable understanding of the clinical trial l... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | [] | The study took the form of a randomized, controlled, double-blind, crossover clinical trial lasting 20 weeks. Subjects (n= 84) were randomly assigned (maintaining the gender ratio of the sample) to one of two treatment sequences involving an oral supplementation (9.9 mg of HT plus 195 mg of PC, and 995.1 mg of maltodex... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['B44-nutrients-11-00640', 'B49-nutrients-11-00640', 'B50-nutrients-11-00640', 'B51-nutrients-11-00640'] | The doses administered in the present work were in agreement with those reported in the literature [44,49,50,51]. Each supplement capsule (SAx) contained 3.3 mg of HT from a standardized olive fruit extract (Mediteanox®, Euromed S.A., Barcelona, Spain), 65 mg of PC from a standardized pomegranate fruit extract (Pomanox... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['B52-nutrients-11-00640'] | All subjects were told to maintain their normal dietary habits and not to increase their consumption of foods rich in antioxidants. The diet of each subject was recorded during the week prior to the beginning and end of each intervention period. All food and beverages consumed inside and outside the home were recorded ... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['B53-nutrients-11-00640'] | Anthropometric measurements were taken at the beginning and end of each intervention period using standard techniques, adhering to international norms set out by the WHO [53]. All measurements were made by trained personnel in the morning with the subject barefoot and wearing only underwear. Body composition was determ... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | [] | Information was collected on medical conditions and the consumption of medications. Blood pressure and heart rate were measured on the right arm using a Spot Vital Signs 420 automatic monitor (Welch Allyn, Madrid, Spain) (accuracy ±5 mmHg). Three measurements were taken at 5-min intervals, and the means were calculated... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['B9-nutrients-11-00640', 'B10-nutrients-11-00640', 'B11-nutrients-11-00640', 'B12-nutrients-11-00640', 'B13-nutrients-11-00640', 'B54-nutrients-11-00640', 'B55-nutrients-11-00640'] | Flow-mediated dilatation (FMD) in the brachial artery was used as an indicator of endothelial function. FMD has been shown to be an independent predictor of CV events [9,10], even in apparently healthy subjects [11,12,13]. Measurements were performed based on recommendations described in published guidelines [54] using... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['B56-nutrients-11-00640', 'B57-nutrients-11-00640', 'B58-nutrients-11-00640'] | At the beginning and end of each intervention period, blood samples were collected early in the morning at the La Paz University Hospital Extraction Unit. Samples were kept at 4–6 °C until analysis, which was always performed within 48 h. The concentration of plasma-soluble vascular cell adhesion molecule-1 (sVCAM-1) w... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | [] | Subjects received the exact number of capsules (in blister packaging) required for each intervention period during a pre-period appointment, and they were asked to return all empty and non-empty blister packages. Compliance was measured at the middle of each intervention period during an interview and at the end of eac... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['B59-nutrients-11-00640'] | A sample size of 38 patients was calculated as the sample size that was necessary to provide 90% power (at α = 0.05) to determine an absolute difference of 2% in FMD [59] (potential 20% dropout included). Quantitative data are presented as the means ± standard deviations (SD). Qualitative data are presented as counts a... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['nutrients-11-00640-f001'] | The study was performed between February and June 2013. Eighty-four apparently healthy subjects (17 men [20.2%], 67 women [79.8%]) were eligible for inclusion. Seventeen subjects were lost to follow-up (8 in the placebo/SAx sequence and 9 in the SAx/placebo sequence) due to personal causes (n= 15) and failure to follow... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['nutrients-11-00640-t001'] | The mean age of the population was 53.0 ± 4.5 years old. The mean BMI was 24.6 ± 3.1 kg/m2. At the start of the study, no significant differences existed between subjects assigned to the supplementation (SAx) and placebo sequences in terms of their anthropometric, vascular function, oxidative status, and other variable... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['nutrients-11-00640-t002'] | No significant differences were detected in any dietetic or anthropometric variables between the start and end of the intervention periods, nor between the periods in terms of changes in these variables (Table 2). | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['nutrients-11-00640-t003', 'nutrients-11-00640-f002'] | Table 3shows the values of the vascular function variables examined. A significant reduction in systolic blood pressure (SBP) was observed at the end of the SAx period (SAx period—start 111.3 ± 12.9, end 101.9 ± 12.0 mmHg,p< 0.001). The reduction in SBP observed after the supplementation treatment was significantly gre... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['nutrients-11-00640-t004'] | Table 4shows the values of the oxidative status variables recorded. Circulating oxLDL levels were reduced significantly after the SAx period (from 108.9 ± 126.2 to 97.44 ± 121.7 ng/mL,p< 0.05); however, no significant reduction was recorded after the placebo period (from 98.86 ± 128.1 to 105.9 ± 139.9 ng/mL). The reduc... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | [] | All subjects ingested >90% of the capsules provided. No significant differences were observed in the number of capsules consumed between the different intervention periods or treatment sequences. No adverse events resulting from the intake of either type of treatment capsule were reported. | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | ['B43-nutrients-11-00640', 'B44-nutrients-11-00640', 'B45-nutrients-11-00640', 'B60-nutrients-11-00640', 'B61-nutrients-11-00640', 'B46-nutrients-11-00640', 'B47-nutrients-11-00640', 'B24-nutrients-11-00640', 'B25-nutrients-11-00640', 'B26-nutrients-11-00640', 'B27-nutrients-11-00640', 'B28-nutrients-11-00640', 'B60-nu... | This is the first clinical trial to study the effect of the regular intake of a supplement rich in HT and PC on early atherosclerosis markers in middle-age subjects. The consumption of three capsules per day containing HT and PC (9.9 mg of HT and 195 mg of PC) for 8 weeks significantly improved endothelial function and... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6470561'] | ['30884808'] | [] | In summary, the consumption of a supplement containing HT and PC (9.9 mg of HT and 195 mg of PC per day) for 8 weeks could help reducing c-LDL oxidation and improved SBP, DBP, and FMD in middle-aged subjects. These improvements in FMD, blood pressure, and circulating oxLDL levels were most pronounced in subjects with a... | PMC6470561 | Article | null | 30,884,808 | Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial | Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. | Nutrients. 2019 Mar 16;11(3):640. doi: 10.3390/nu11030640. | Quirós-Fernández R | Nutrients | 2,019 | 2019/03/20 | PMC6470561 | null | 10.3390/nu11030640 | oa_comm/txt/all/PMC6470561.txt | 4880ef8e074ed82ab40c9b22d3284a61 | Nutrients. 2019 Mar 16; 11(3):640 | 2021-06-19 03:48:10 | CC BY | no |
['PMC6051678'] | ['29924768'] | ['B1', 'B2', 'B3', 'B4', 'B5', 'B5', 'B6', 'B4', 'B5', 'B7', 'B8', 'B9'] | Since the discovery of adult mesenchymal stem cells (MSCs), extensive research has been conducted to determine their mechanisms of differentiation and effectiveness in cell therapy and regenerative medicine. MSCs can be isolated from several cell extracts, and some of the most accessible extracts are from the oral cavi... | PMC6051678 | Research; Oral Surgery | null | 29,924,768 | Autologous dental pulp mesenchymal stem cells for inferior third molar post-extraction socket healing: A split-mouth randomised clinical trial | Barbier L, Ramos E, Mendiola J, Rodriguez O, Santamaria G, Santamaria J, Arteagoitia I. | Med Oral Patol Oral Cir Bucal. 2018 Jul 1;23(4):e469-e477. doi: 10.4317/medoral.22466. | Barbier L | Med Oral Patol Oral Cir Bucal | 2,018 | 2018/06/21 | PMC6051678 | null | 10.4317/medoral.22466 | oa_comm/txt/all/PMC6051678.txt | 332875d8062e740e887396f015f70492 | Med Oral Patol Oral Cir Bucal. 2018 Jul 21; 23(4):e469-e477 | 2021-06-18 17:29:13 | CC BY | no |
['PMC6051678'] | ['29924768'] | ['B10', 'F1', 'F2', 'B11', 'B11', 'F3', 'F1', 'F2'] | We designed an independent, single-centre, double-blind, randomised, split-mouth controlled clinical trial. The trial was approved by the Ethical Committee of Clinical Investigation of Cruces University Hospital (Protocol number EC20141) and registered on the EudraCT database (number: 2014-001913-18). It was conducted ... | PMC6051678 | Research; Oral Surgery | null | 29,924,768 | Autologous dental pulp mesenchymal stem cells for inferior third molar post-extraction socket healing: A split-mouth randomised clinical trial | Barbier L, Ramos E, Mendiola J, Rodriguez O, Santamaria G, Santamaria J, Arteagoitia I. | Med Oral Patol Oral Cir Bucal. 2018 Jul 1;23(4):e469-e477. doi: 10.4317/medoral.22466. | Barbier L | Med Oral Patol Oral Cir Bucal | 2,018 | 2018/06/21 | PMC6051678 | null | 10.4317/medoral.22466 | oa_comm/txt/all/PMC6051678.txt | 332875d8062e740e887396f015f70492 | Med Oral Patol Oral Cir Bucal. 2018 Jul 21; 23(4):e469-e477 | 2021-06-18 17:29:13 | CC BY | no |
['PMC6051678'] | ['29924768'] | ['T1', 'T2', 'T3'] | Recruitment began in March 2015. The first patient underwent extractions in May 2015 and the last patient underwent extractions in February 2017. In total, 32 patients were recruited; two were excluded because they were unable to undergo a CT scan at 6 months after the extraction. The final sample consisted of 30 patie... | PMC6051678 | Research; Oral Surgery | null | 29,924,768 | Autologous dental pulp mesenchymal stem cells for inferior third molar post-extraction socket healing: A split-mouth randomised clinical trial | Barbier L, Ramos E, Mendiola J, Rodriguez O, Santamaria G, Santamaria J, Arteagoitia I. | Med Oral Patol Oral Cir Bucal. 2018 Jul 1;23(4):e469-e477. doi: 10.4317/medoral.22466. | Barbier L | Med Oral Patol Oral Cir Bucal | 2,018 | 2018/06/21 | PMC6051678 | null | 10.4317/medoral.22466 | oa_comm/txt/all/PMC6051678.txt | 332875d8062e740e887396f015f70492 | Med Oral Patol Oral Cir Bucal. 2018 Jul 21; 23(4):e469-e477 | 2021-06-18 17:29:13 | CC BY | no |
['PMC6051678'] | ['29924768'] | ['B12', 'B13', 'B14', 'B7', 'B8', 'B4', 'B5', 'B6', 'B9', 'B4', 'B5', 'B6', 'B9', 'B15', 'B16', 'B2'] | This manuscript was written in accordance with the recommendations of the CONSORT 2010 Declaration (12). Our objective was to assess the effect of ADPMSCs on limiting socket bone resorption after ITM extraction. Regenerative medicine aims to repair damaged tissues with cell therapy procedures. It is based on the use of... | PMC6051678 | Research; Oral Surgery | null | 29,924,768 | Autologous dental pulp mesenchymal stem cells for inferior third molar post-extraction socket healing: A split-mouth randomised clinical trial | Barbier L, Ramos E, Mendiola J, Rodriguez O, Santamaria G, Santamaria J, Arteagoitia I. | Med Oral Patol Oral Cir Bucal. 2018 Jul 1;23(4):e469-e477. doi: 10.4317/medoral.22466. | Barbier L | Med Oral Patol Oral Cir Bucal | 2,018 | 2018/06/21 | PMC6051678 | null | 10.4317/medoral.22466 | oa_comm/txt/all/PMC6051678.txt | 332875d8062e740e887396f015f70492 | Med Oral Patol Oral Cir Bucal. 2018 Jul 21; 23(4):e469-e477 | 2021-06-18 17:29:13 | CC BY | no |
['PMC6964112'] | ['31969977'] | ['CR1', 'CR2', 'CR3', 'CR4', 'CR5', 'CR6', 'CR7', 'CR8', 'CR9', 'CR10', 'CR11', 'CR12', 'CR13', 'CR14', 'CR8', 'CR10', 'CR11', 'CR14', 'CR15', 'CR16', 'CR17', 'CR18', 'CR20', 'CR21', 'CR22', 'CR8', 'CR9', 'CR17'] | Autism spectrum disorder (ASD) is characterized by lifelong impairments in social and communicative functioning, and the presence of stereotyped behaviors and interests [1]. In the past decade, intranasal administration of the neuropeptide oxytocin (OT) has increasingly been explored as a potential pharmacological trea... | PMC6964112 | Research | null | 31,969,977 | Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up | Bernaerts S, Boets B, Bosmans G, Steyaert J, Alaerts K. | Mol Autism. 2020 Jan 15;11(1):6. doi: 10.1186/s13229-020-0313-1. eCollection 2020. | Bernaerts S | Mol Autism | 2,020 | 2020/01/24 | PMC6964112 | null | 10.1186/s13229-020-0313-1 | oa_comm/txt/all/PMC6964112.txt | 4f1b87bb5194c7a07b8becc3f905d158 | Mol Autism. 2020 Jan 15; 11:6 | 2021-06-19 04:55:42 | CC BY | no |
['PMC6964112'] | ['31969977'] | ['Fig1'] | This two-arm, double-blind, randomized, placebo-controlled parallel study was performed at the Leuven University Hospital (Leuven, Belgium) to assess multiple-dose effects of intranasal oxytocin (OT) administration on core autism characteristics and experience of attachment in adult men with ASD. A specific aim of this... | PMC6964112 | Research | null | 31,969,977 | Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up | Bernaerts S, Boets B, Bosmans G, Steyaert J, Alaerts K. | Mol Autism. 2020 Jan 15;11(1):6. doi: 10.1186/s13229-020-0313-1. eCollection 2020. | Bernaerts S | Mol Autism | 2,020 | 2020/01/24 | PMC6964112 | null | 10.1186/s13229-020-0313-1 | oa_comm/txt/all/PMC6964112.txt | 4f1b87bb5194c7a07b8becc3f905d158 | Mol Autism. 2020 Jan 15; 11:6 | 2021-06-19 04:55:42 | CC BY | no |
['PMC6964112'] | ['31969977'] | ['CR1', 'CR23', 'CR24', 'CR25', 'Tab1', 'MOESM1', 'Fig1', 'CR8', 'CR9', 'CR17'] | Forty high-functioning adult men with a formal diagnosis of ASD were recruited between April 2015 and December 2016 from the Autism Expertise Centre at the Leuven University Hospital. The diagnosis was established by a multidisciplinary team (child psychiatrist and/or expert neuropediatrician, psychologist, speech/lang... | PMC6964112 | Research | null | 31,969,977 | Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up | Bernaerts S, Boets B, Bosmans G, Steyaert J, Alaerts K. | Mol Autism. 2020 Jan 15;11(1):6. doi: 10.1186/s13229-020-0313-1. eCollection 2020. | Bernaerts S | Mol Autism | 2,020 | 2020/01/24 | PMC6964112 | null | 10.1186/s13229-020-0313-1 | oa_comm/txt/all/PMC6964112.txt | 4f1b87bb5194c7a07b8becc3f905d158 | Mol Autism. 2020 Jan 15; 11:6 | 2021-06-19 04:55:42 | CC BY | no |
['PMC6964112'] | ['31969977'] | ['CR26', 'CR27', 'CR6', 'CR28', 'CR29', 'CR29', 'CR17', 'CR30', 'MOESM1', 'Tab2', 'MOESM1', 'MOESM1'] | Participants were assigned to receive the OT or PL treatment based on a computer-generated randomized order. Except for the manager of randomization, all research staff conducting the trial, participants, and their parents and/or partners were blinded to treatment allocation. OT (Syntocinon®, Sigma-tau) and PL (saline ... | PMC6964112 | Research | null | 31,969,977 | Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up | Bernaerts S, Boets B, Bosmans G, Steyaert J, Alaerts K. | Mol Autism. 2020 Jan 15;11(1):6. doi: 10.1186/s13229-020-0313-1. eCollection 2020. | Bernaerts S | Mol Autism | 2,020 | 2020/01/24 | PMC6964112 | null | 10.1186/s13229-020-0313-1 | oa_comm/txt/all/PMC6964112.txt | 4f1b87bb5194c7a07b8becc3f905d158 | Mol Autism. 2020 Jan 15; 11:6 | 2021-06-19 04:55:42 | CC BY | no |
['PMC6964112'] | ['31969977'] | ['MOESM1', 'CR31', 'CR32', 'CR33', 'CR34', 'CR35'] | The Social Responsiveness Scale (for adults) (SRS-A) total score was used as the primary outcome measure (self-report and informant-based versions). The other behavioral questionnaires were considered secondary: Repetitive Behavior Scale-Revised (RBS-R); State Adult Attachment Measure (SAAM); Inventory of Parent and Pe... | PMC6964112 | Research | null | 31,969,977 | Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up | Bernaerts S, Boets B, Bosmans G, Steyaert J, Alaerts K. | Mol Autism. 2020 Jan 15;11(1):6. doi: 10.1186/s13229-020-0313-1. eCollection 2020. | Bernaerts S | Mol Autism | 2,020 | 2020/01/24 | PMC6964112 | null | 10.1186/s13229-020-0313-1 | oa_comm/txt/all/PMC6964112.txt | 4f1b87bb5194c7a07b8becc3f905d158 | Mol Autism. 2020 Jan 15; 11:6 | 2021-06-19 04:55:42 | CC BY | no |
['PMC6964112'] | ['31969977'] | ['Fig1', 'Tab2', 'CR36', 'Tab2'] | For each questionnaire, baseline differences between groups were assessed using two-samplettests. To assessbetween-group differences, pre-to-post difference scores were calculated for each assessment session (T1, T2, T3) and difference scores were subjected to a linear mixed-effects model (one-tailed) with the random f... | PMC6964112 | Research | null | 31,969,977 | Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up | Bernaerts S, Boets B, Bosmans G, Steyaert J, Alaerts K. | Mol Autism. 2020 Jan 15;11(1):6. doi: 10.1186/s13229-020-0313-1. eCollection 2020. | Bernaerts S | Mol Autism | 2,020 | 2020/01/24 | PMC6964112 | null | 10.1186/s13229-020-0313-1 | oa_comm/txt/all/PMC6964112.txt | 4f1b87bb5194c7a07b8becc3f905d158 | Mol Autism. 2020 Jan 15; 11:6 | 2021-06-19 04:55:42 | CC BY | no |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.